Ney Carter Borges: Bempedoic Acid and Venous Thromboembolism Risk in Statin-Intolerant Patients
Ney Carter Borges, Member Cardiologist of Global Physician Association at Cleveland Clinic Florida, shared on LinkedIn:
”Bempedoic Acid and Venous Thromboembolism Risk in Statin-Intolerant Patients
In this post hoc analysis of the CLEAR Outcomes randomized clinical trial, investigators evaluated whether bempedoic acid reduces the risk of venous thromboembolism (VTE) in statin-intolerant patients at high cardiovascular risk.
A total of 13,970 participants (mean age 65.5 years; 48.2% women) were randomized to bempedoic acid 180 mg daily or placebo and followed for a median of 40.6 months.
During follow-up, 106 VTE events occurred.
Bempedoic acid was associated with a significant 42% relative reduction in VTE compared with placebo (39 vs 67 events; HR 0.58, 95% CI 0.39–0.86; P=0.006).
Consistent benefits were observed for both major components of VTE: deep vein thrombosis (HR 0.56, 95% CI 0.31–0.996; P=0.045) and pulmonary embolism (HR 0.61, 95% CI 0.37–0.996; P=0.046).
These findings extend previous evidence suggesting that lipid-lowering therapies may provide protection beyond atherosclerotic cardiovascular disease, potentially reducing thrombotic events through anti-inflammatory effects, lipoprotein(a) reduction, and enhanced clearance of coagulation factors.
Importantly, the observed reduction in VTE persisted even after accounting for major cardiovascular events.
Although limited by its post hoc design and the relatively small number of VTE events, this analysis suggests that bempedoic acid may offer an additional clinical benefit in statin-intolerant patients by lowering both cardiovascular and venous thromboembolic risk.
These results should be considered hypothesis-generating and warrant prospective confirmation.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 16:51Suzan Nakasendwa: A Growing Stroke Challenge in Uganda
-
Oct 20, 2026, 16:38Steve Moon: How Does Smoking Cessation Duration Affect Ischemic Stroke Risk
-
Oct 20, 2026, 16:25Cedrice Mentor: Reducing Platelet Wastage Through Cold Storage
-
Oct 20, 2026, 16:09Thirunavukkarasu Angappan: Can a Purified Fibrinogen Concentrate Replace Cryoprecipitate
-
Oct 20, 2026, 16:01Kalyan Roy: Platelet Conservation Through Evidence-Based Transfusion Practice
-
Oct 20, 2026, 15:28Stacy E. Croteau: 33 Countries, One Mission – Better Bleeding Disorder Care
-
Oct 20, 2026, 15:19Teresa Barnes: What Does a Pulmonary Embolism Mean for Jalen Hurts?
-
Oct 20, 2026, 15:04Laura S.: Could Speaking Up Prevent Maternal Deaths from Thrombosis?
-
Oct 20, 2026, 14:44Pete Stibbs: VTE in Professional Athletes – When Fitness Is Not Enough